1. Academic Validation
  2. Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation

Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation

  • Bioact Mater. 2022 Mar 17;18:91-103. doi: 10.1016/j.bioactmat.2022.03.013.
Shichen Liu 1 2 Yao Sun 2 Teng Zhang 1 2 Longtao Cao 2 Zhiwei Zhong 1 Haoxin Cheng 2 3 Qingqing Wang 2 Zhuang Qiu 2 4 Weimin Zhou 1 Xiaolei Wang 2 3
Affiliations

Affiliations

  • 1 Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, 330006, PR China.
  • 2 The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, PR China.
  • 3 College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, PR China.
  • 4 School of Public Health & Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang, Jiangxi, 330088, PR China.
Abstract

Thromboembolism is the leading cause of cardiovascular mortality. Currently, for the lack of targeting, short half-life, low bioavailability and high bleeding risk of the classical thrombolytic drugs, pharmacological thrombolysis is usually a slow process based on micro-pumping. In addition, frequently monitoring and regulating coagulation functions are also required during (and after) the process of thrombolysis. To address these issues, a targeted thrombolytic and anticoagulation nanoplatform (UCATS-UK) is developed based on upconversion nanoparticles (UCNPs) that can convert 808 or 980 nm near-infrared (NIR) LIGHT into UV/blue LIGHT. This nanoplatform can target and enrich in the thrombus site. Synergistic thrombolysis and anticoagulation therapy thus could be realized through the controlled release of urokinase (UK) and nitric oxide (NO). Both in vitro and in vivo experiments have confirmed the excellent thrombolytic and anticoagulative capabilities of this multifunctional nanoplatform. Combined with the unique fluorescent imaging capability of UCNPs, this work is expected to contribute to the development of clinical thrombolysis therapy towards an integrated system of imaging, diagnosis and treatment.

Keywords

Anticoagulation; Controlled release; Targeted drug delivery; Thrombus; Upconversion nanoparticles.

Figures
Products